1)Ravery V, Fizazi K, Oudard S, et al:The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU Int 108:1782-1786, 2011
2)Eisenberger MA and Sinibaldi VW:The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later. Oncology 20:853-862, 2006
3)Tannock IF, Osoba D, Stockler MR, et al:Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer:a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
4)Tannock IF, de Wit R, Berry WR, et al:Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
5)Petrylak DP, Tangen CM, Hussain MH, et al:Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
6)Berthold DR, Pond GR, Soban F, et al:Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008
7)Armstrong AJ, Tannock IF, de Wit R, et al:The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46:517-525, 2010
8)Sella A, Sternberg CN, Skoneczna I, et al:Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int 102:1607-1609, 2008
9)Berthold DR, Pond GR, Roessner M, et al:Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone:relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14:2763-2767, 2008
10)Sweeney CJ, Chen YH, Carducci M, et al:Chemohormonil therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 273:737-746, 2015
11)Gravis G, Fizazi K, et al:Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer(GETUG-AFU 15):a randomised, open-label, phase 3 trial. The Lancet Oncol 14:149-158, 2013
12)Tombal B:What is the pathophysiology of a hormone-resistant prostate tumour? Eur J Cancer 47(Suppl 3):S179-188, 2011
13)Vrignaud P, Semiond D, Lejeune P, et al:Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 19:2973-2983, 2013
14)Bahl A, Masson S, Birtle A, et al:Second-line treatment options in metastatic castration-resistant prostate cancer:a comparison of key trials with recently approved agents. Cancer Treat Rev 40:170-177, 2014
15)Bahl A, Oudard S, Tombal B, et al:Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24:2402-2408, 2013
16)Nozawa M, Mukai H, Takahashi S, et al:Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol 20:1026-1034, 2015
17)Sonpavde G, Wang CG, Galsky MD, et al:Cytotoxic chemotherapy in the contemporary management of metastatic prostate cancer. BJU Int 116:17-29, 2014
18)Pouessel D, Oudard S, Gravis G, et al: [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:the TROPIC study in France]. Bull Cancer 99:731-741, 2012